Exchange: NASDAQ·Updated 07:30 PM EST

GPCR News

News
all
press releases
Structure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low - What's Next?
Structure Therapeutics (NASDAQ:GPCR) Reaches New 52-Week Low - Here's What Happened...
MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low - What's Next?
Structure Therapeutics (NASDAQ:GPCR) Reaches New 52-Week Low - Here's What Happened...
MarketBeat
More News
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Research analysts at HC Wainwright dropped their FY2026 EPS estimates for Structure Therapeutics in a report issued on Thursday, November 12th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of...
MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fifteen research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven...
MarketBeat
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
Zacks
NVO's Wegovy pill generated DKK 5.4 billion in Q3 sales, boosting obesity growth amid expanding global access and intensifying GLP-1 competition.
Zacks
NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
Zacks
NVO faces intensifying GLP-1 competition, earnings cuts and pricing pressure, challenging its growth outlook ahead of Q3 results.
Zacks
Lilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.
Zacks
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
Zacks
LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.
Zacks

Advertisement|Remove ads.